Вторая фаза клинических испытаний дала обнадеживающие результаты
: Keryx reports positive results from Phase II study of kidney disease drug
Wed. June 10, 2009; Posted: 05:04 AM
Jun 10, 2009 (Datamonitor via COMTEX) -- US-based Keryx Biopharmaceuticals has reported positive results of the Phase II study of Zerenex for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on thrice weekly hemodialysis.
The study was a multicenter, open-label clinical trial, which enrolled 55 patients. The primary objective of this study was to assess the tolerability and safety of Zerenex (ferric citrate) with doses ranging from approximately 1gm per day to 12gm per
Читать дальше »